GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dimerix Ltd (ASX:DXB) » Definitions » Institutional Ownership

Dimerix (ASX:DXB) Institutional Ownership : 0.07% (As of May. 27, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Dimerix Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Dimerix's institutional ownership is 0.07%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Dimerix's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Dimerix's Float Percentage Of Total Shares Outstanding is 0.00%.


Dimerix Institutional Ownership Historical Data

The historical data trend for Dimerix's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dimerix Institutional Ownership Chart

Dimerix Historical Data

The historical data trend for Dimerix can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.07 0.07 0.07 0.09 0.09 0.09 0.09 0.09 0.07 0.07

Dimerix Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Dimerix (ASX:DXB) Business Description

Traded in Other Exchanges
N/A
Address
425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Dimerix (ASX:DXB) Headlines

No Headlines